PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, which Co. is developing for the reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled main or life-threatening bleeding or requiring urgent surgery or an invasive procedure. Co.'s second product candidate, PB1046, is a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB6440 is a selective aldosterone synthase inhibitor being developed for treatment-resistant hypertension. The PHAS stock yearly return is shown above.
The yearly return on the PHAS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PHAS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|